bendamustine (Treanda®) 

OFFICE ADMINISTERED

Indication(s) for Prior Authorization:

  • Chronic lymphocytic leukemia (CLL)
  • (Classical) Hodgkin Lymphoma, refractory/relapsed
  • Multiple Myeloma, refractory/relapsed
  • Non-Hodgkin’s lymphoma
  • Waldenstrom’s macroglobulinemia/lymphoplasmacytic lymphoma

Patients must meet all the following criteria for the indication above:

Chronic lymphocytic leukemia (CLL)

  • First line therapy with or without rituximab for stage II-IV disease OR
  • With or without rituximab for relapsed or refractory disease

Hodgkin Lymphoma, refractory/relapsed

  • Diagnosis of refractory or relapsed Hodgkin Lymphoma
  • Third line therapy, failure of two prior chemotherapeutic regimens

Multiple Myeloma, refractory/relapsed

  • Diagnosis of refractory or relapsed Multiple Myeloma

Non-Hodgkin’s lymphoma, subtypes as listed

  • Aids-related B-cell lymphoma
  • Diffuse large B-cell lymphoma
  • Follicular lymphoma
  • Gastric MALT lymphoma
  • Mantle Cell Lymphoma
  • Non-Gastric MALT lymphoma
  • Primary cutaneous B-Cell Lymphoma
  • Splenic marginal zone lymphoma
  • Indolent B-cell lymphoma

Indolent B-cell lymphoma

  • That has progressed during or within six months of treatment with rituximab or a rituximab containing regimen

Waldenstrom’s macroglobulinarmia/lyphoplasmacytic lymphoma

  • Diagnosis of Waldenstrom’s macroglobulinarmia/lyphoplasmacytic lymphoma

The following indications do not meet the criteria for use established by the Western Health Advantage Pharmacy and Therapeutics Committee:

  • Disease states not listed above

Dosing:

Chronic lymphocytic leukemia (CLL)

  • Up to 100 mg/m2 IV infusion on days 1 and 2 of each 28 day cycle.

Hodgkin Lymphoma, refractory/relapsed

  • Up to 120mg/m2 IV infusion on days 1 and 2 of each 28 day cycle.

Multiple Myeloma, refractory/relapsed

  • Up to 100 mg/m2 IV infusion on days 1 and 2 of each 28 day cycle.

Non-Hodgkin’s lymphoma, any subtype listed above

  • Up to 120mg/m2 IV infusion on days 1 and 2 of each 21 day cycle.

Waldenstrom’s macroglobulinarmia/lyphoplasmacytic lymphoma

  • Up to 90 mg/m2 IV infusion on days 1 and 2 (or days 2 and 3) of each 28 day cycle, total dose/cycle = 180mg/m2 OR
  • Up to 90 mg/m2 IV infusion on days 8 and 9, 36 and 37, 64 and 65, 92 and 93, total dose = 720mg/m2

 

Last review date: December 1, 2014

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar